NCT02550249

Neoadjuvant Nivolumab in Glioblastoma

Phase II Study of Neoadjuvant Nivolumab in Patients With Glioblastoma Multiforme

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Clinica Universidad de Navarra, Universidad de Navarra · Academic / Other
• Sex: All
• Age: 1 Year
• Healthy volunteers: Not accepted

Summary

Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.

Detailed description

Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery until toxicity or progression.

Conditions

• Glioblastoma Multiforme

Interventions

Type	Name	Description
DRUG	Nivolumab	Intravenous administration of nivolumab

Timeline

• Start date: 2015-06-01
• Primary completion: 2017-03-01
• Completion: 2017-03-01
• First posted: 2015-09-15
• Last updated: 2017-04-11

Locations

1 site across 1 country: Spain